Neurohumoral control of gallbladder motility in healthy subjects and diabetic patients with or without autonomic neuropathy.
Patients affected by diabetes mellitus are reported to have an increased incidence of gallbladder abnormalities. The pathophysiologic mechanisms for this phenomenon are unclear. In the present study ultrasonography was used to determine gallbladder emptying in response to a meal or separate cephalic or hormonal stimulation in 21 diabetic patients and 10 healthy subjects. Gallbladder emptying and refilling after a meal were similar in diabetic patients and healthy subjects. When diabetics were divided according to the presence or absence of cardiac autonomic neuropathy (AN), a significant reduction of gallbladder emptying in response to cephalic stimulation was found in diabetics with AN (P less than 0.01 in comparison with diabetics without AN or healthy subjects). A dose-response curve of gallbladder emptying in response cerulein, a cholecystokinin analog, at concentrations of 0.25, 1, and 4 micrograms/kg/min was evaluated. No differences of gallbladder emptying were found in the three groups of subjects, indicating that gallbladder sensitivity to hormonal stimulation is not changed in diabetic patients with or without AN. Diabetic patients with AN have a significant reduction of gastric acid output and pancreatic polypeptide (PP) secretion in response to cephalic stimulation (P less than 0.05 in comparison with diabetic patients without AN or healthy subjects). Cerulein-induced PP secretion was similar in all three groups of subjects (P greater than 0.05). This study indicates that in diabetic patients with AN, gallbladder emptying as well as gastric acid and PP secretions induced by neural stimulation are markedly reduced in comparison to diabetics without AN.
Istituti di Clinica Medica I, Università di Perugia, Italy.
S
S
Fiorucci
R
R
Bosso
L
L
Scionti
S
S
DiSanto
B
B
Annibale
G
G
Delle Fave
A
A
Morelli
D000328:Adult; D001342:Autonomic Nervous System Diseases / Q000503:physiopathology*; D002108:Ceruletide; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003929:Diabetic Neuropathies / Q000503:physiopathology*; D005260:Female; D005502:Food; D005704:Gallbladder / Q000503:physiopathology*; D005744:Gastric Acid / Q000378:metabolism; D006801:Humans; D008297:Male; D010191:Pancreatic Polypeptide / Q000378:metabolism; D010528:Peristalsis / Q000502:physiology; D014463:Ultrasonography
D010191:Pancreatic Polypeptide; D002108:Ceruletide